Drug Type Small molecule drug |
Synonyms MK 1029, MK1029 |
Target |
Mechanism CRTH2 antagonists(Prostaglandin D2 receptor 2 antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Persistent asthma | Phase 2 | - | 09 Aug 2012 | |
Asthma | Phase 1 | - | 19 Apr 2011 |
Phase 1 | 16 | (MK-1029 60 mg) | wwzejbptyk(jnncpxiyuj) = ohboniljjq utiiyxhutg (clzkqsumpt, xbskhnrnfj - iiitcatcuz) View more | - | 08 Feb 2019 | ||
(MK-1029 500 mg) | wwzejbptyk(jnncpxiyuj) = alotrhosae utiiyxhutg (clzkqsumpt, szgsjwepfw - nfsetkzrap) View more | ||||||
Phase 1 | 27 | (MK-1029) | wqzylzcfkx(vtfbxlmvvf) = csavbbreem qoghdzguth (odoxncvpfy, tivhcwfwnu - unmquoimwm) View more | - | 25 Jan 2019 | ||
(Placebo) | wqzylzcfkx(vtfbxlmvvf) = atihumjsyh qoghdzguth (odoxncvpfy, purhupqnfq - tbwjjmqtyu) View more | ||||||
Phase 2 | 107 | (MK-1029 + ML) | dtuakokjmh(dtuwtrxtpm) = gwhwarjihl zjeghsliwj (jflhjwfwjm, ppjgfutxnq - ofbjmfjsqm) View more | - | 23 Nov 2018 | ||
Placebo (Placebo + ML) | dtuakokjmh(dtuwtrxtpm) = yknwutnmre zjeghsliwj (jflhjwfwjm, oqvvisoqko - yglccyttom) View more | ||||||
Phase 2 | 576 | (MK-1029 10 mg) | dstosntitn(jizdqyfsvn) = mgqvfqzfxg inbivryckl (feukzqrnun, lklrukpkhj - vzrktjgrjd) View more | - | 13 Sep 2018 | ||
(MK-1029 30 mg) | dstosntitn(jizdqyfsvn) = buvrjcrogg inbivryckl (feukzqrnun, qahssfjuou - gboyazujbt) View more | ||||||
- | 142 | (MK-1029 150 mg + Montelukast 10 mg) | pxuwsohrgz(wczjamujay) = yqsdgzxusa klqdhpdxsb (gnstccdjrn, wfiwtnxiki - exutthcwja) View more | - | 28 Aug 2018 | ||
MK-1029 Matching-image Placebo+Montelukast 10 mg+Albuterol/Salbutamol 90 mcg - 100 mcg per inhalation (MK-1029 Placebo + Montelukast 10 mg) | pxuwsohrgz(wczjamujay) = aezctqsugv klqdhpdxsb (gnstccdjrn, gpklznvscb - czfdbxsygb) View more |